. Author manuscript; available in PMC: 2021 Apr 8.

Published in final edited form as: Aliment Pharmacol Ther. 2020 Apr 24;51(11):1031–1038. doi: 10.1111/apt.15719

Table 4.

Endpoints for Combinations of Dual Biologic Therapy (DBT)

	Endoscopic Improvement	Endoscopic Remission	Clinical Response	Clinical Remission	Adverse Events

vedolizumab / ustekinumab	63% (5/8)	25% (2/8)	71% (5/7)^‡	57% (4/7)^‡	13% (1/8)
vedolizumab / TNF-antagonist	33% (4/12)^†	25% (3/12)^†	42% (5/12)^‡	33% (4/12)^‡	15% (2/13)
ustekinumab / TNF-antagonist	33% (1/3)^†	33% (1/3)^†	33% (1/3)	33% (1/3)	0% (0/3)

All DBT trials	43% (10/23)^†	26% (6/23)^†	50% (11/22)^‡	41% (9/22)^‡	13% (3/24)

^†

Endoscopic endpoint data not yet available in four trials; three were considered failure of DBT due to surgery or entering a clinical trial (two vedolizumab/TNF-antagonist, one ustekinumab/TNF-antagonist) – one was awaiting follow-up but achieved clinical response (vedolizumab/TNF-antagonist).

^‡

PRO-2 unable to be calculated in two trials due to presence of an ostomy (one in vedolizumab/ustekinumab and one in vedolizumab/TNF-antagonist).